Marrero RJ, Shastri VM, Nicolet D, Mrózek K, Walker CJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Uy GL, Stock W, Carroll AJ, Byrd JC, Aplenc R, Cooper TM, Gamis AS, Wu H, Pounds S, Wang YC, Alonzo TA, Meshinchi S, Eisfeld AK, Kolb EA, Lamba JK. Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid Leukemia. JAMA Netw Open. 2025 Jun 2;8(6):e2516296. doi: 10.1001/jamanetworkopen.2025.16296. PMID: 40549387; PMCID: PMC12186577.
Study ID Citation
Abstract
In this cohort study with 1086 patients, a low ACS10 score was associated with inferior event-free survival in pediatric, adolescent, and young adult patients when treated with a standard induction regimen. There was a higher abundance of low ACS10 scores in Black patients, but the results suggested that observed racial difference could be overcome by therapy augmentation, such as the addition of bortezomib.